Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MXCT vs SGHT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SGHT Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)

SGHT Overall Winner 6-Pillar Tally: MXCT 1 – 4 SGHT (1 Tie) Matrix Metrics: MXCT 2 – 6 SGHT

As of Nov 20, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas SGHT carries 53.2/100 (HOLD) at $10.18 (N/M Forward P/E, -20.2% operating margin).

  • Growth vs. Quality Trade-Off: SGHT earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. MXCT 41.7/100 SELL) and 1.09β · 48% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MXCT vs SGHT
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25
SGHT NASDAQ Head-to-Head Winner
Sight Sciences, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$10.18
-4.14% 1D
Market Cap $590.2M
TTM Revenue $88M
Forward P/E N/M
Beta / 30D Vol 1.09β · 48% Vol
Unified Composite Score
53.2 / 100 HOLD
Tech 39.0 Fund 54.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.4% over 20 days), RSI 54
RSI-14: 54.2 · SMA20: $10.07 · SMA50: $9.21

6-Pillar Scorecard Institutional Category Breakdown (MXCT 1 – 4 SGHT)

Columns: Metric · MXCT · SGHT
1. Valuation Multiples MXCT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.9x 6.3x
2. Growth & Scale SGHT
Revenue Growth (YoY) +48.7% +25.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $34M $88M
Market Cap $132.2M $590.2M
3. Profitability & Quality SGHT
Gross Margin 81.0% 87.7%
Operating Margin -85.5% -20.2%
Net Profit Margin -81.4% -32.1%
Return on Equity (ROE) -16.9% -50.1%
4. Balance Sheet & Cash Flow SGHT
Cash Generation (TTM) -$24M -$17M
Cash Flow Margin -69.2% -19.1%
Net Cash / Leverage $2.2M Net Debt (0.11x D/E) $35M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGHT
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 78.7% (8th %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MXCT (2) vs SGHT (6)
Institutional Metric MXCT SGHT Criterion Row Edge
Market Capitalization
Scale
$132.2M $590.2M Larger Scale SGHT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+48.7% +25.2% Higher Growth MXCT
Operating Margin (TTM)
Profitability
-85.5% -20.2% Higher Margin SGHT
Net Profit Margin
Profitability
-81.4% -32.1% Higher Margin SGHT
Return on Equity (ROE)
Capital Efficiency
-16.9% -50.1% Higher ROE MXCT
52-Week Range Position
Momentum
63% ($1–$2) 83% ($3–$12) Stronger Trend SGHT
Beta / 30D Volatility
Risk Regime
1.19β · 96% Vol 1.09β · 48% Vol Lower Realized Risk SGHT
Unified Institutional Score
Composite Signal
41.7 / 100 (SELL) 53.2 / 100 (HOLD) Higher Composite SGHT
Trailing 12M Revenue (USD)
Operating Scale
$34M $88M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
81.0% 87.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.9x EV/Rev N/M PEG · 6.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($2.2M Net Debt (0.11x D/E)) -$17M ($35M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGHT +16.19 pp
MXCT: -4.2% · SGHT: +11.99%
3M Horizon SGHT +22.92 pp
MXCT: -1.44% · SGHT: +21.48%
6M Horizon SGHT +70.66 pp
MXCT: +31.73% · SGHT: +102.39%
1Y Horizon SGHT +66.31 pp
MXCT: -19.41% · SGHT: +46.9%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MXCT Revenue SGHT Revenue MXCT Op. Margin SGHT Op. Margin Margin Leader
FY2019 $10M N/A -93.7% N/A MXCT
FY2020 $20M $30M -71.6% -116.5% MXCT
FY2021 $20M $50M -84.3% -105.2% MXCT
FY2022 $30M $70M -95.2% -117.7% MXCT
FY2023 $20M $80M -247.7% -70.7% SGHT
FY2024 $20M $80M -230.5% -63.3% SGHT
FY2025 $20M $80M -247.6% -48.0% SGHT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGHT CONSOLIDATION
37d in phase · OBV NEUTRAL
Current IV 78.7%
IV Percentile 8th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SGHT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SGHT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $590.2M market capitalization and -20.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MXCT vs SGHT Key Questions & Quantitative Answers

As of Nov 20, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas SGHT carries 53.2/100 (HOLD) at $10.18 (N/M Forward P/E, -20.2% operating margin). Growth vs. Quality Trade-Off: SGHT earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. MXCT 41.7/100 SELL) and 1.09β · 48% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

SGHT leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with SGHT at +25.2% YoY revenue growth and +0.0% YoY earnings growth on $88M TTM revenue (87.7% gross margin, -20.2% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), MXCT cumulative revenue shifted +100.0% while SGHT shifted +166.7%. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SGHT.

MXCT screens cheaper on headline valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas SGHT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.3x EV/Revenue (-19.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus SGHT (-50.1% ROE) capital efficiency.

In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, SGHT carries 78.7% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.09β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.